Cleveland Clinic & Anixa submit IND for their breast cancer vaccine
Category: #health  By Saipriya Iyer  Date: 2020-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cleveland Clinic & Anixa submit IND for their breast cancer vaccine

Anixa Biosciences, Inc., a renowned biotechnology firm primarily focused on the prevention and treatment of cancer as well as other infectious diseases, has reportedly announced that a new IND application for the company’s innovative breast cancer vaccine candidate has been submitted to the United States FDA.

The vaccine technology is being innovated by a Cleveland Clinic research team, which was led and supervised by Dr. Vincent Tuohy, from Lerner Research Institute, Cleveland Clinic. The biotechnology giant has a global and exclusive license to the said technology.

Moreover, the vaccine technology is being effectively developed at the Cleveland Clinic, and has received substantial funding from the United States Department of Defense. This funding is further anticipated to allow completion of the two separate Phase 1 clinical stage trials.

Dr. Tuohy, stated that if the trial data results showcase outcomes that are like the ones gotten from pre-clinical studies, the breast cancer vaccine might possibly have a substantial effect on breast cancer, which is a highly common malignancy seen in women.

Dr. Amit Kumar, President & CEO, Anixa Biosciences, stated that the firm is looking ahead to move this new technology into clinical development.

Dr. Kumar further added that if the human trial data is similar to the animal data, then the retired protein hypothesis of Dr. Tuohy would pave a novel way of preventing breast cancer and other kinds of tumors.

Dr. G. Thomas Budd, the Clinical Investigator for the trial, who is from Taussig Cancer Center, Cleveland Clinic, stated that the first clinical trial would be conducted in women that are diagnosed with early stage, high-risk triple negative breast cancer and are getting standard care at the Cleveland Clinic.

Dr. Budd further added that the expert team is looking ahead to start the Phase I trial as well as assess the diagnosed patients.

Source credit: https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-file-ind-application-for-breast-cancer-vaccine-301178420.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

EU starts mass COVID-19 vaccination program in 27 member-states
EU starts mass COVID-19 vaccination program in 27 member-states
By Saipriya Iyer

The European Union has recently started a mass COVID-19 vaccination campaign to inoculate over 450 million individuals in 27 member-states.

EU leaders have reportedly negotiated var...

Asus announces plans to strengthen its offline retail presence in India
Asus announces plans to strengthen its offline retail presence in India
By Saipriya Iyer

AsusTek Computer Inc., popularly known as Asus, has reportedly announced plans to strengthen its offline retail presence across India. The firm, which had 7.5% of total market share in the Indian PC segment in the Q3 o...

Need for efficient sea vessels to augment marine turbocharger deployment
Need for efficient sea vessels to augment marine turbocharger deployment
By Saipriya Iyer

Increasing globalization and the subsequent rise in seaborne trade activities are fueling the global marine turbochargers industry size. These trends have created a significant demand for commercial vessels. Growth of ...